Trial Profile
Multi-center, Double-blind, Randomized, Placebo-controlled, Active-reference, Parallel-group, Polysomnography Dose-response Study to Assess the Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs Daridorexant (Primary) ; Zolpidem
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
- 12 Jul 2023 Results of post-hoc analysis of two studies (NCT02839200 & NCT03545191) assessing the effect of daridorexant on the number, duration, and distribution of night-time wake bouts, and their correlation with daytime functioning, published in the CNS Drugs.
- 10 Mar 2022 According to an Idorsia Pharmaceuticals media release, data from this study will be presented at World Sleep 2022.
- 17 Jan 2020 Results published in the Annals of Neurology